pomalidomide has been researched along with p5091 in 1 studies
| Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) | Studies (p5091) | Trials (p5091) | Recent Studies (post-2010) (p5091) |
|---|---|---|---|---|---|
| 623 | 121 | 552 | 24 | 0 | 23 |
| Protein | Taxonomy | pomalidomide (IC50) | p5091 (IC50) |
|---|---|---|---|
| Ubiquitin carboxyl-terminal hydrolase 7 | Homo sapiens (human) | 4.2 | |
| Ubiquitin carboxyl-terminal hydrolase 47 | Homo sapiens (human) | 4.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, W; Li, J; Liu, X; Shi, J; Zhang, Z; Zhao, L; Zhou, Y | 1 |
1 review(s) available for pomalidomide and p5091
| Article | Year |
|---|---|
A review on the treatment of multiple myeloma with small molecular agents in the past five years.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Deubiquitinating Enzymes; Drug Development; Drug Resistance; Histone Deacetylases; Humans; Ikaros Transcription Factor; Immunomodulating Agents; Models, Molecular; Morpholines; Multiple Myeloma; Phthalimides; Piperidones; Proteasome Inhibitors; Treatment Outcome; Ubiquitin-Protein Ligases | 2022 |